This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (311) Pharmacology and Pharmaceutics (66) Digital Pain Assessment and Management (164)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/55129, first published .
Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

Dexmedetomidine Versus Midazolam for End-of-Life Sedation and Agitation: Protocol for a Randomized Controlled Trial (The DREAMS Trial)

Authors of this article:

Benjamin Thomas1, 2 Author Orcid Image ;   Greg Barclay1, 2 Author Orcid Image ;   Wing-Shan Angela Lo2 Author Orcid Image ;   Judy Mullan1 Author Orcid Image ;   Kylie Mansfield1 Author Orcid Image
Article Authors Cited by Tweetations Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.